Retina

Researchers have found that study participants with healthy eyes and no history of AMD had thinner retinas if they carried the genes that put them at risk.

For 72 straight hours, the study volunteer lay in a bed at UT Southwestern, the monotony broken only at night when researchers placed his lower body in a sealed, vacuum-equipped sleeping bag to pull down body fluids that naturally flowed into his head while supine.

Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.

In light of another unprecedented year filled with technological advancements and pivots as a result of the pandemic, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2022.

A team of scientists have developed a two-photon excited fluorescence scanning laser ophthalmoscope, an instrument that allows viewing the biochemistry of vision in the living eye in real time.

The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, both part of UC San Diego Health, received funding from the Nixon Visions Foundation that will support studies of the PRPH2 gene linked to macular dystrophy and boost stem cell research aimed at developing early diagnosis and a cure.

A team of researchers from Thomas Jefferson University have found that immune cells could be doing much more than first thought in protecting our eyes.

Closing out his discussion on the port delivery system in retinal diseases, Chirag Jhaveri, MD, considers how this approach has impacted the treatment landscape.

Real-world evidence is growing in importance as a source of information that can help support clinical decision-making when evaluated properly.

The company anticipates that the Sirius and Celeste studies will further validate QR-421a’s ability to stabilize vision loss in people with USH2A mediated retinitis pigmentosa and Usher syndrome.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

Concise insight on education and training strategies that will optimize use of the port delivery system in retinal diseases.

Chirag Jhaveri, MD, reviews the trial design and results of the LADDER and ARCHWAY studies, which tested the port delivery system in neovascular AMD.

According to Yvonne Ou, MD, the test can objectively detect relative changes in the on and off pathways.

Expert insight on the history of the port delivery system in neovascular AMD and how it has impacted patient experience and outcomes.

Triamcinolone acetonide injection approved for treatment of macular edema.

Investigators hoping to develop a novel artificial intelligence model.

Proposal hints at the use of generative adversarial network (GAN) for applications in macular surgery

Mark Wieland, MD, explores how Port Delivery System with ranibizumab provides drug delivery over an extended period.

Veeral Sheth, MD, presents research finding faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular edema (DME) compared with other retinal treatments.

Ines Lains, MD, PhD, explores how mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.

Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

Roger A. Goldberg, MD, MBA, notes how small misalignments in the plunger can lead to possible overdosing.

Ajay Kuriyan, MD, discusses fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting.

Gareth Lema, MD, PhD, spotlights a treatment could provide benefits for patients with central retinal artery occlusion.

Dilsher Dhoot, MD, reports results of the KESTREL and KITE trials, in which brolucizumab was compared with aflibercept for treating diabetic macular edema.

Retinal and choroidal changes were observed in study.

The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).

Patients can get real-time disease monitoring with self-operated device.